文献速递血栓与止血

体重调整利伐沙班治疗儿童静脉血栓栓塞症(EINSTEIN-Jr):三项多中心单臂2期研究结果

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
PubMed 文献 · Lancet Haematol · 2019-08-13

三项多中心单臂2期研究评估体重调整利伐沙班治疗儿童静脉血栓栓塞症,共纳入93例儿童,主要安全终点无大出血,4%发生临床相关非大出血,无复发性静脉血栓栓塞症,确认体重≥20 kg的给药方案可达到目标成人暴露。

要点

  • 体重调整利伐沙班在儿童中安全性良好,无大出血发生。
  • 体重≥20 kg的儿童确认了达到目标成人暴露的给药方案。

核心结论

  • 体重调整利伐沙班在儿童中安全性良好,确认的给药方案将在3期试验中评估。

研究设计与样本

  • 三项多中心单臂2期研究,在澳大利亚、欧洲、以色列、日本和北美54个中心进行。
  • 纳入93例儿童,年龄从小于6个月到17岁,既往接受抗凝治疗至少2个月或导管相关血栓至少6周。

主要发现

  • 75例重复影像学检查中,24例(32%)血栓负荷完全消退,43例(57%)改善,8例(11%)无变化,无恶化。

关键数值与推荐

  • 体重≥30 kg儿童每日一次给药,体重≥20 kg且<30 kg儿童每日两次给药可达到目标成人暴露。
  • 低体重儿童(<20 kg,尤其<12 kg)暴露量低,未来研究已修订剂量。

临床怎么用

  • 对于体重≥20 kg的儿童静脉血栓栓塞症患者,可考虑使用体重调整利伐沙班治疗。
  • 低体重儿童需使用修订后的剂量方案,尚待3期试验验证。

局限性

  • 单臂设计,无对照组。
  • 样本量小,尤其低年龄组。
  • 低体重儿童暴露量低,需修订剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rivaroxaban has been shown to be efficacious for treatment of venous thromboembolism in adults, and has a reduced risk of bleeding compared with standard anticoagulants. We aimed to develop paediatric rivaroxaban regimens for the treatment of venous thromboembolism in children and adolescents. METHODS: In this phase 2 programme, we did three studies to evaluate rivaroxaban treatment in children younger than 6 months, aged 6 months to 5 years, and aged 6-17 years. Our studies used a multicentre, single-arm design at 54 sites in Australia, Europe, Israel, Japan, and north America. We included children with objectively confirmed venous thromboembolism previously treated with low-molecular weight heparin, fondaparinux, or a vitamin K antagonist for at least 2 months or, in children who had catheter-related venous thromboembolism for at least 6 weeks. We administered rivaroxaban orally in a bodyweight-adjusted 20 mg-equivalent dose, based on physiologically-based pharmacokinetic modelling predictions and EINSTEIN-Jr phase 1 data in young adults, in either a once-daily (tablets; for those aged 6-17 years), twice-daily (in suspension; for those aged 6 months to 11 years), or three times-daily (in suspension; for those younger than 6 months) dosing regimen for 30 days (or 7 days for those younger than 6 months). The primary aim was to define rivaroxaban treatment regimens that match the target adult exposure range. The principal safety outcome was major bleeding and clinically relevant non-major bleeding. Analyses were per-protocol. The predefined efficacy outcomes were symptomatic recurrent venous thromboembolism, asymptomatic deterioration on repeat imaging at the end of the study treatment period. These trials are registered at ClinicalTrials.gov, numbers NCT02564718, NCT02309411, and NCT02234843. FINDINGS: Between Feb 11, 2013, and Dec 20, 2017, we enrolled 93 children (ten children younger than 6 months; 15 children aged 6 months to 1 year; 25 children aged 2-5 years; 32 children aged 6-11 years; and 11 children aged 12-17 years) into our study. 89 (96%) children completed study treatment (30 days of treatment, or 7 days in those younger than 6 months), and 93 (100%) children received at least one dose of study treatment and were evaluable for the primary endpoints. None of the children had a major bleed, and four (4%, 95% CI 1·2-10·6) of these children had a clinically relevant non-major bleed (three children aged 12-17 years with menorrhagia and one child aged 6-11 years with gingival bleeding). We found no symptomatic recurrent venous thromboembolism in any patients (0%, 0·0-3·9). 24 (32%) of 75 patients with repeat imaging had their thrombotic burden resolved, 43 (57%) patients improved, and eight (11%) patients were unchanged. No patient deteriorated. We confirmed therapeutic rivaroxaban exposures with once-daily dosing in children with bodyweights of at least 30 kg and with twice-daily dosing in children with bodyweights of at least 20 kg and less than 30 kg. Children with low bodyweights (<20 kg, particularly <12 kg) showed low exposures so, for future studies, rivaroxaban dosages were revised for these weight categories, to match the target adult exposure range. 61 (66%) of 93 children had adverse events during the study. Pyrexia was the most common adverse event (ten [11%] events), and anaemia and neutropenia or febrile neutropenia were the most frequent grade 3 or worse events (four [4%] events each). No children died or were discontinued from rivaroxaban because of adverse events. INTERPRETATION: Treatment with bodyweight-adjusted rivaroxaban appears to be safe in children. The treatment regimens that we confirmed in children with bodyweights of at least 20 kg and the revised treatment regimens that we predicted in those with bodyweights less than 20 kg will be evaluated in the EINSTEIN-Jr phase 3 trial in children with acute venous thromboembolism. FUNDING: Bayer AG, Janssen Research and Development.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019. PMID: 31420317. doi:10.1016/S2352-3026(19)30161-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。